A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 10 2020
Historique:
received: 11 06 2020
accepted: 25 09 2020
entrez: 24 10 2020
pubmed: 25 10 2020
medline: 5 11 2020
Statut: epublish

Résumé

Antigens displayed on self-assembling nanoparticles can stimulate strong immune responses and have been playing an increasingly prominent role in structure-based vaccines. However, the development of such immunogens is often complicated by inefficiencies in their production. To alleviate this issue, we developed a plug-and-play platform using the spontaneous isopeptide-bond formation of the SpyTag:SpyCatcher system to display trimeric antigens on self-assembling nanoparticles, including the 60-subunit Aquifex aeolicus lumazine synthase (LuS) and the 24-subunit Helicobacter pylori ferritin. LuS and ferritin coupled to SpyTag expressed well in a mammalian expression system when an N-linked glycan was added to the nanoparticle surface. The respiratory syncytial virus fusion (F) glycoprotein trimer-stabilized in the prefusion conformation and fused with SpyCatcher-could be efficiently conjugated to LuS-SpyTag or ferritin-SpyTag, enabling multivalent display of F trimers with prefusion antigenicity. Similarly, F-glycoprotein trimers from human parainfluenza virus-type 3 and spike-glycoprotein trimers from SARS-CoV-2 could be displayed on LuS nanoparticles with decent yield and antigenicity. Notably, murine vaccination with 0.08 µg of SARS-CoV-2 spike-LuS nanoparticle elicited similar neutralizing responses as 2.0 µg of spike, which was ~ 25-fold higher on a weight-per-weight basis. The versatile platform described here thus allows for multivalent plug-and-play presentation on self-assembling nanoparticles of trimeric viral antigens, with SARS-CoV-2 spike-LuS nanoparticles inducing particularly potent neutralizing responses.

Identifiants

pubmed: 33097791
doi: 10.1038/s41598-020-74949-2
pii: 10.1038/s41598-020-74949-2
pmc: PMC7584627
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antigens 0
Bacterial Proteins 0
Multienzyme Complexes 0
Recombinant Proteins 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
6,7-dimethyl-8-ribityllumazine synthase 89287-46-7
Ferritins 9007-73-2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

18149

Commentaires et corrections

Type : UpdateOf

Références

N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
mBio. 2019 Feb 26;10(1):
pubmed: 30808695
Front Immunol. 2019 Dec 12;10:2931
pubmed: 31921185
Vaccine. 2019 Oct 8;37(43):6405-6414
pubmed: 31515145
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
J Virol. 2003 May;77(10):5889-901
pubmed: 12719582
Nature. 2013 Jul 4;499(7456):102-6
pubmed: 23698367
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
Nanomedicine. 2019 Feb;16:69-78
pubmed: 30529790
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
Malar J. 2016 Nov 8;15(1):545
pubmed: 27825348
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
mBio. 2017 Feb 28;8(1):
pubmed: 28246356
Nature. 2019 Jun;570(7762):468-473
pubmed: 31142836
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
J Mol Biol. 2009 Jul 3;390(1):83-98
pubmed: 19427319
Sci Rep. 2016 Jan 19;6:19234
pubmed: 26781591
J Virol. 2014 Dec;88(24):14002-16
pubmed: 25253346
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Virol. 2006 Oct;80(19):9896-8
pubmed: 16973594
Nat Commun. 2015 Jul 28;6:7712
pubmed: 26218507
PLoS One. 2008 Jun 25;3(6):e2547
pubmed: 18575629
J Nanobiotechnology. 2016 Apr 27;14:30
pubmed: 27117585
Comput Struct Biotechnol J. 2015 Nov 26;14:58-68
pubmed: 26862374
J Virol. 2018 Oct 29;92(22):
pubmed: 30185594
Mol Ther. 2016 May;24(5):1003-12
pubmed: 26686385
Cell. 2019 Mar 7;176(6):1420-1431.e17
pubmed: 30849373
J Mol Biol. 1994 Sep 30;242(4):470-86
pubmed: 7932704
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7
pubmed: 22366317
Curr Opin Chem Biol. 2015 Dec;29:94-9
pubmed: 26517567
Cell. 2016 May 5;165(4):813-26
pubmed: 27114034
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12265-12270
pubmed: 30420505
Immunity. 2018 Aug 21;49(2):301-311.e5
pubmed: 30076101
Cell. 2018 Mar 8;172(6):1319-1334
pubmed: 29522750
Nat Med. 2015 Sep;21(9):1065-70
pubmed: 26301691
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Cell Rep. 2020 Oct 27;33(4):108322
pubmed: 33091382
Sci Immunol. 2020 May 1;5(47):
pubmed: 32358170
J Struct Biol. 1996 Jan-Feb;116(1):190-9
pubmed: 8742743
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
Curr Opin Immunol. 2019 Aug;59:57-64
pubmed: 31029910
Nat Struct Mol Biol. 2016 Sep;23(9):811-820
pubmed: 27478931
J Mol Biol. 2001 Mar 9;306(5):1099-114
pubmed: 11237620
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
Nat Commun. 2016 Jun 28;7:12041
pubmed: 27349934
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701

Auteurs

Baoshan Zhang (B)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Cara W Chao (CW)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Yaroslav Tsybovsky (Y)

Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Olubukola M Abiona (OM)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Geoffrey B Hutchinson (GB)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Juan I Moliva (JI)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Adam S Olia (AS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Amarendra Pegu (A)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Emily Phung (E)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Institute for Biomedical Sciences, George Washington University, Washington, DC, USA.

Guillaume B E Stewart-Jones (GBE)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Raffaello Verardi (R)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Lingshu Wang (L)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Shuishu Wang (S)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Anne Werner (A)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Eun Sung Yang (ES)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Christina Yap (C)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Tongqing Zhou (T)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

John R Mascola (JR)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Nancy J Sullivan (NJ)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Barney S Graham (BS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Kizzmekia S Corbett (KS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Peter D Kwong (PD)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. pdkwong@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH